2 results
Approved WMOCompleted
CORE PERIODPrimary:* Evaluate the safety and tolerability of up to 24 weeks of AG-348 administration in patients with pyruvate kinase deficiency (PK deficiency).Secondary:* Evaluate the pharmacokinetics (PK) of AG-348 and the metabolite AGI-8702.*…
Approved WMORecruiting
The aim of this study is to determine whether treatment with spinal cord stimulation in patients with refractory angina pectoris leads to a significant reduction in myocardial ischemia. Other aims are to determine the effect of this treatment on the…